Enlivex Therapeutics (NASDAQ: ENLV) — Perfil da empresa, notícias e dados financeiros
Enlivex Therapeutics is a biotechnology firm developing immunotherapies for severe medical conditions like sepsis and COVID-19, aiming to innovate
Enlivex Therapeutics
Enlivex Therapeutics (TASE:ENLV), (NASDAQ: ENLV) is a biotechnology company focused on developing novel therapies for severe medical conditions with unmet needs, including sepsis, COVID-19, and solid tumors. Its operations span from early-stage preclinical research to advanced clinical trials, aiming to harness the body's immune system to fight these critical conditions more effectively. Enlivex's projects include Allocetra™, an innovative immunotherapy designed to rebalance the immune system in life-threatening situations. The objective of Enlivex is to advance its pipeline of treatments through clinical development, striving to provide new solutions for patients facing diseases with limited treatment options.
Resumo
Operações
Produtos e/ou serviços de Enlivex Therapeutics
- Allocetra™, an immunotherapy for life-threatening conditions like sepsis and COVID-19 complications.
- Developing treatments for solid tumors through CAR-T and TCR platforms.
- Therapies targeting GvHD in bone marrow transplant patients.
- Research on prevention and treatment of acute kidney injury.
- Advancements in autoimmune disease therapies, focusing on rebalancing the immune system.
- Pipeline projects exploring novel approaches to organ transplant acceptance.
equipe executiva do Enlivex Therapeutics
- Shai NovikExecutive Chairman
- Oren HershkovitzChief Executive Officer
- Dror MevorachFounder & Scientific Advisor
- Shachar ShlosbergerChief Financial Officer
- Veronique Amor-BaroukhChief Operating Officer
- Sigal AradDirector of Human Resources
- Einat GalamidiChief Medical Officer
Principais indicadores financeiros
Resultados divulgados pela Enlivex Therapeutics, em USD.
- Cap. de mercado
- 4,1 mi
- Receita (TTM)
- 0
- P/L
- 0.0
- LPA (diluído, TTM)
- 8320.6
- Dividend yield
- —
- Margem de lucro
- 0.0%
| Fim do ano fiscal | Receita | Resultado operacional | Lucro líquido |
|---|---|---|---|
| 0 | -15 mi | 1,2 bi | |
| 0 | -15,5 mi | -15 mi | |
| 0 | -29,4 mi | -29,1 mi | |
| 0 | -25,8 mi | -31,1 mi |